Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 3, 2024 08:30AM
Inozyme Pharma Inc. (INZY) Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 Apr 8, 2024 06:34AM
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency Apr 8, 2024 06:30AM
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 5, 2024 06:00PM
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference Apr 2, 2024 08:30AM


Mar 26, 2024 08:30AM Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
Mar 12, 2024 08:30AM Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
Feb 26, 2024 08:30AM Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
Feb 6, 2024 08:30AM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 5, 2023 08:30AM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 9, 2023 08:30AM Inozyme Pharma to Participate in Upcoming Investor Conferences
Nov 7, 2023 08:30AM Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
Nov 3, 2023 04:15PM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 26, 2023 08:30AM Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
Oct 10, 2023 08:30AM Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
Oct 6, 2023 08:30AM Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
Sep 26, 2023 07:30AM Inozyme Pharma (INZY) Reports Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701
Sep 26, 2023 07:30AM Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
Sep 20, 2023 08:30AM Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
Sep 6, 2023 08:30AM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 5, 2023 08:30AM Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 8, 2023 08:30AM Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
Aug 3, 2023 04:01PM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 26, 2023 07:31AM Inozyme Pharma (INZY) Issues Updates on Global Development Strategy of INZ-701
Jul 26, 2023 07:30AM Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
Jul 19, 2023 08:30AM Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023
Jun 27, 2023 08:30AM Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
Jun 2, 2023 07:30AM Inozyme Pharma to Present at the Jefferies Healthcare Conference
May 9, 2023 08:30AM Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
Apr 14, 2023 08:33AM Inozyme Pharma Inc. (INZY) to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial
Apr 14, 2023 08:30AM Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
Apr 11, 2023 08:30AM Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference
Apr 4, 2023 08:30AM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer
Mar 22, 2023 08:30AM Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights
Mar 1, 2023 08:30AM Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference
Feb 16, 2023 07:30AM Inozyme Pharma (INZY) Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
Feb 16, 2023 07:30AM Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
Feb 6, 2023 07:30AM Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023
Jan 9, 2023 08:30AM Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress
Dec 5, 2022 08:30AM Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency
Dec 1, 2022 07:30AM Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
Nov 10, 2022 08:30AM Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates
Nov 7, 2022 07:30AM Inozyme Pharma to Participate in Upcoming Investor Conferences
Nov 3, 2022 07:30AM Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
Oct 31, 2022 07:31AM Inozyme Pharma (INZY) Announces Publication of Comprehensive ENPP1 Variant Database
Oct 31, 2022 07:30AM Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database